Cachexia
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Cachexia is a moderately active landscape with 36 programs across 24 companies. The most active players are AVEO Pharmaceuticals, Inc., Genfleet Therapeutics (Shanghai) Inc., Jiangsu Nutai Biologics Co., Ltd. 3 therapies are approved with 7 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
AVEO Pharmaceuticals, Inc.
1 program
Genfleet Therapeutics (Shanghai) Inc.
1 program
Jiangsu Nutai Biologics Co., Ltd
1 program
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
1 program
Immune Response BioPharma, Inc.
1 program
Acacia Pharma Ltd
1 program
Pipeline
Programs by Phase
Analysis
Modality Breakdown
85%
Small molecule
33 of 39 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 39 classified programs, each share of the total. Modality classified for 98% of 42 pipeline programs.
Analysis
Trial Status
37
clinical trials
Clinical Trials
Trial Activity
37 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)